A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
Latest Information Update: 26 Sep 2023
Price :
$35 *
At a glance
- Drugs Docetaxel (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 07 Sep 2023 Results assessing the molecular features of post-treated PCa along with long-term clinical outcomes to explore mechanisms of response and resistance to chemohormonal therapy , published in the Journal of the National Cancer Institute
- 29 Mar 2021 Results of an analysis assessing treatment outcomes in men with clinically localized high-risk cancer to determine cancer progression after treatment published in the Journal of Urology
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology